WDB Medical Data, Inc., a U.S. subsidiary of WDB Holdings Co., Ltd. and global provider of CRO and R&D services to the biopharmaceutical and medical device industries, has acquired DZS Clinical Services, a provider of clinical development and data analytics for pharma, biopharma and medical device companies.
 
The acquisition bolsters WDB’s full-service CRO capabilities to provide more comprehensive and global services to U.S. companies with coverage in Europe and Japan. Services include clinical development and clinical operations support, data management, statistical services, medical writing, pharmacovigilance and regulatory affairs.
 
“This acquisition and the addition of Greg Ambra and the DZS operations team complement our company and further our goal to provide even greater flexibility and affordability to more businesses and institutions worldwide,” said Norifumi Ninokata, president and chief executive officer of WDBMD.
 
“Access to WDBMD’s expertise and global resources will increase our capacity and allow us to offer a broader range of services to our clients,” said Greg Ambra, president of DZS Clinical Services. 
 
The DZS Clinical Services leadership team will remain along with its facilities in Bound Brook, NJ, and its new office in Sunnyvale, CA, to foster relationships with its West Coast-based clients. WDBMD, headquartered in Princeton, NJ, also operates its CRO business out of offices in Japan, India and Finland.